REFERENCES:

Blanshard C et al. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. JID 172:622-8, 1995.

Boivin G et al. Evaluation of the cytomegalovirus DNA load and polymorphonuclear leukocytes (PMNL) of HIV-infected patients using quantitative PCR (Q-PCR). Abstract #11, 3rd Conf on Human Retro and Opport Infect, Washington DC, 1996.

Cinque P et al. Ganciclovir therapy for cytomegalovirus infection of the central nervous system in AIDS patients: Monitoring by CMV-DNA detection in cerebrospinal fluid. JID 171: 1603-6, 1995.

Cochereau-Massin I et al. Intravitreal ganciclovir: a 3-year experience. Abstract 023, Third European Conference on Clinical Aspects and Treatment of HIV Infection. Paris, 1992.

Cribbin K et al. Intravitreal ganciclovir in patients resistant to ganciclovir and /or foscarnet. Abstract PoB 3159, VIII Intl Conf AIDS, Amsterdam, 1992.

Crumpacker C et al. Oral vs. intravenous ganciclovir (GCV) as maintenance treatment of newly diagnosed cytomegalovirus retinitis (CMVR) in AIDS. 1st Nat Conf Hum Retrov, Abstract 538: 154, 1993.

Dieterich D et al. Ganciclovir treatment of cytomegalovirus colitis in AIDS: A randomized, double-blind, placebo-controlled multicenter study. JID 167: 278- 282, 1993.

Dietrich D et al. Treatment of gastrointestinal cytomegalovirus infection using twice daily administration of foscarnet in AIDS patients. 1st Nat Conf Hum Retrov Abstract 5l3: 146, 1993.

Drew WL et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. NEJM 333: 615-20, 1995.

Drew WL et al. Failure of acyclovir to suppress excretion in symptomatic HIV antibody-positive patients. Abstract 1115, 32nd ICAAC, Anaheim, 1992.

Drew WL et al. Prevalence of ganciclovir resistant cytomegalovirus during oral ganciclovir prophylaxis. Abstract #LB 16, 3rd Conf on Human Retro and Opport lnfect, Washington DC, 1996.

Feinburg J et al. Phase III study of valacyclovir for cytomegalovirus prophylaxis in patients with advanced HIV disease. 35th ICAAC, Abstract #1214, San Francisco, 1995.

Jabs D et al. Combination therapy for retinitis: Results of ACTG 228. 20th ACTG, Washington DC, 1995.

Jacobson MA et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS 8: 451-459, 1994.

Jacobson MA et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. JID 168: 444 448, 1993.

Jacobson MA et al. Randomized phase I study of combined vs. alternating foscarnet (PFA)/ganciclovir (GCV) maintenance therapy (Rx) for CMV retinitis. 32nd ICAAC, Abstract #1223, 1992.

Kirsch LS et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 119:466-76, 1995.

Kirsch LS et al. Intravitreal cidofovir treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102: 533- 42, 1995.

Kupperman B et al. A randomized controlled multicenter trial of sustained- release intraocular ganciclovir implant in AIDS patients with CMV retinitis. 35th ICAAC, Abstract #1215, San Francisco, 1995.

Lalezari J et al. A randomized controlled study of cidofovir for relapsing cytomegalovirus retinitis in patients with AIDS. 35th ICAAC, Abstract #LB-9, San Francisco, 1995.

Martin EF et al. Treatment of cytomegalovirus retinitis with an intraocular sustained -released ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 112: 1521-1539, 1994.

Meinert CL et al. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnett or ganciclovir for cytomegalovirus retititis. NEJM 326(4): 213-220, 1992.

Nightingale SD et al. An intraocular slow-releasing ganciclovir drug delivery system for treatment of CMV retititis. VII Intl Conf AIDS, Florence. Vol 2: 245 (W.B.2255), 1991.

Polis M et al. A phase I/II dose escalation trial of (s)-1-[3-hydroxy- 2- (Phosphonymethoxy)propyl]cytosine (HPMPC) in HIV-infected peersons with CMV viruria. 33rd ICAAC Abstract #98, 1993.

Salzberger B el al. Foscarnet and ganciclovir commbination therapy for severe CMV-disease in HIV-infected patients. Abstract PO-BO8-1233, IX Intl Conf AIDS, Berlin, 1993.

Spector S et al. Pharmacokinetics, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. JID 171:1431-7, 1995.

Spector S et al. A randomizcd, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. JID 168: 557-563, 1993.

Squires K et al. Oral ganciclovir (POG) versus intravenous ganiclovir (IVG) maintenance therapy for cytomeglovirus (CMV) retinitis in patients with AIDS: preliminary results of a phase III study. 1st Nat Conf Hm Retrov, Abstract 540: 154, 1993.

Verdejo J et al. Intravenous ganciclovir for cytomegalovirus treatment (CMV) retinitis. Abstract PoB 3175, VIII Intl Conf AIDS, Amsterdam 1992.

Volker K et al. Intravenous versus oral ganciclovir. European/Austrailian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrance in patients with AIDS. AIDS 9: 471-477, 1995.

Youle M et al. Effects of high-dose acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo- controlled study, AIDS 8: 641-649, 1994.

OTHER REPORTS:
Balfour H et al. A Randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. NEJM 320(21): 1381-7, 1990.

Lalezari JP et al. The safety, pharmacokinetics, and anti-CMV activity of weekly HPMPC in HIV-positive patients excreting CMV. 1st Nat Conf Hum Retrov, Abstract 541: 154, 1993.

Leach CT et al. A longitudinal study of cytomegalovirus infection in human immunodeficiency virus type 1-seropositive homosexual men: molecular epidemiology and association with disease progression. J Infect Dis 170: 293- 298, 1994.

Medina DJ et al. Ganciclovir antagonizes the anti-human immunodeficiency virus type-1 activity of zidovudine and didanosine in vitro. Ant Agnt Chemo 36(5): 1127-1130, 1992.

Nelson M et al. Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immunodeficiency syndrome. Am J Gastroenterology. 86(7): 876-881, 1991.

Plotkin SA et al. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 265: 1393-1395, 1994.